TY - JOUR
T1 - Characteristics and outcome of chronic myeloid leukemia patients with F317l BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
AU - Jabbour, Elias
AU - Kantarjian, Hagop M.
AU - Jones, Dan
AU - Reddy, Neeli
AU - O'Brien, Susan
AU - Garcia-Manero, Guillermo
AU - Burger, Jan
AU - Cortes, Jorge
PY - 2008/12/15
Y1 - 2008/12/15
N2 - Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%) after dasatinib (P=.001). Median follow-up from mutation detection was 25 months.At the time of F317L, 8 patients were in chronic phase (CP), 6 in accelerated phase, and 6 in blast phase. There was no difference in characteristics between patients with or without F317Lmutations, or with no mutations. A complete cytogenetic response was acheived in 3 of 6 patients treated with nilotinib, 2 of 2 with imatinib, and 0 of 3 with dasatinib. Survival of patients with F317L was similar to those with other mutations (P = .45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage.
AB - Mutations in codon 317 after treatment with imatinib and dasatinib have been reported. We reviewed patients with chronic myeloid leukemia and mutations after tyrosine kinase inhibitor (TKI) therapy. F317L was detected in 20, including 12/99 (12%) with mutation after imatinib failure, and 8/16 (50%) after dasatinib (P=.001). Median follow-up from mutation detection was 25 months.At the time of F317L, 8 patients were in chronic phase (CP), 6 in accelerated phase, and 6 in blast phase. There was no difference in characteristics between patients with or without F317Lmutations, or with no mutations. A complete cytogenetic response was acheived in 3 of 6 patients treated with nilotinib, 2 of 2 with imatinib, and 0 of 3 with dasatinib. Survival of patients with F317L was similar to those with other mutations (P = .45). Patients in CP had better outcome, with a 2-year survival of 75%. F317L mutation is resistant to dasatinib but sensitive to other TKIs. The prognosis is dependent mostly on the disease stage.
UR - http://www.scopus.com/inward/record.url?scp=58149380741&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149380741&partnerID=8YFLogxK
U2 - 10.1182/blood-2008-04-149948
DO - 10.1182/blood-2008-04-149948
M3 - Article
C2 - 18818391
AN - SCOPUS:58149380741
SN - 0006-4971
VL - 112
SP - 4839
EP - 4842
JO - Blood
JF - Blood
IS - 13
ER -